Published Date: 30-Nov-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Atopic Dermatitis Drugs Market size is expected to reach $22 billion by 2028, rising at a market growth of 9.2% CAGR during the forecast period.
The Oral segment is showcasing a CAGR of 9.4% during (2022 - 2028). Only in severe situations, when the disease has spread to vast portions of the body, or in the event of any complications with previous treatments, are oral corticosteroids administered. Azathioprine, methotrexate, cyclosporine, and mycophenolate mofetil are some of the common oral drugs.
The Biologics segment is leading the Global Atopic Dermatitis Drugs Market by Class in 2021 thereby, achieving a market value of $8.5 billion by 2028. Since biologics target the inflammatory mechanisms causing the disease rather than just treating the symptoms, they have a significant therapeutic benefit over traditional topical therapies. These medications have a competitive advantage due to their great specificity. In severe circumstances, such as second or third-line treatment for patients who have not responded to previous systemic medications, biologics are typically administered.
The North America market dominated the Global Atopic Dermatitis Drugs Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $9.5 billion by 2028.The Europe market is exhibiting a CAGR of 9% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 10.1% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Pfizer Inc., Sanofi SA, AbbVie Inc., Galderma S.A., Eli Lilly and Company, Leo Pharma A/S, Regeneron Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Novartis AG, and Incyte Corporation.
By Route of Administration
Unique Offerings from KBV Research